Johnson & Johnson temporarily halts Covid-19 vaccine output: report
NYSE - LSE
| RYCEF | 1.17% | 14.5 | $ | |
| CMSC | -0.52% | 22.95 | $ | |
| BTI | 0.99% | 56.4 | $ | |
| GSK | -1.55% | 36.75 | $ | |
| RIO | 0.65% | 60.09 | $ | |
| BP | 0.83% | 33.88 | $ | |
| NGG | 0.03% | 72.3 | $ | |
| RELX | -3.65% | 48.81 | $ | |
| SCU | 0% | 12.72 | $ | |
| VOD | 1.77% | 11.3 | $ | |
| RBGPF | 1.42% | 76 | $ | |
| AZN | -1.2% | 73.6 | $ | |
| BCC | -4.64% | 82.92 | $ | |
| SCS | 0.19% | 15.99 | $ | |
| CMSD | 0.13% | 23.54 | $ | |
| JRI | 0.6% | 13.34 | $ | |
| BCE | -1.33% | 23.25 | $ |
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.
J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.
"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.
J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.
Z.Kontos--AN-GR
